Bellus Health to Present at BioFinance 2012
LAVAL, QC, May 25, 2012, 2012 (Menafn - Canada NewsWire via COMTEX) --BELLUS Health Inc. ("BELLUS Health" or the "Company") today advised that Roberto Bellini, President and Chief Executive Officer, will present at BioFinance 2012. The presentation will take place at 11:20 am Eastern Time on Wednesday, May 30(th), 2012. The conference will be held at the St. Andrew's Club & Conference Centre in Toronto, Ontario.
BioFinance is the leading investor conference in Canada for the life sciences industry. This event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector. Presenting companies span a range of industries including: biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company, in collaboration with its partner, Celtic Therapeutics Inc., is currently advancing its novel drug candidate KIACTATM, through a Phase III trial for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and eventually death. AA amyloidosis affects approximately 50,000 individuals in the United States, Europe and Japan.
To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/May2012/25/c2716.html
SOURCE: BELLUS HEALTH INC.
Jonathan Ross TMX Equicom 416-815-0700 ext. 248 firstname.lastname@example.org
Copyright (C) 2012 CNW Group. All rights reserved.